Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 23031530)

  • 1. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
    Jiang T; Zhang Z; Zhang Y; Lv H; Zhou J; Li C; Hou L; Zhang Q
    Biomaterials; 2012 Dec; 33(36):9246-58. PubMed ID: 23031530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
    Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
    Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction of artesunate nanoparticles modified by hyaluronic acid and cell-penetrating peptides and its inhibitory effect on cancer cells in vitro].
    Li J; Jin S; Dong XR; Han XF; Wang MY
    Zhongguo Zhong Yao Za Zhi; 2018 Sep; 43(18):3668-3675. PubMed ID: 30384531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-functional bio-derived nanoparticulates for apoptotic antitumor therapy.
    Ding Y; Wang Y; Opoku-Damoah Y; Wang C; Shen L; Yin L; Zhou J
    Biomaterials; 2015 Dec; 72():90-103. PubMed ID: 26344366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids.
    Mo R; Sun Q; Li N; Zhang C
    Biomaterials; 2013 Apr; 34(11):2773-86. PubMed ID: 23352118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.
    Kuai R; Yuan W; Qin Y; Chen H; Tang J; Yuan M; Zhang Z; He Q
    Mol Pharm; 2010 Oct; 7(5):1816-26. PubMed ID: 20701288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models.
    Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z
    J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery.
    Song E; Han W; Li C; Cheng D; Li L; Liu L; Zhu G; Song Y; Tan W
    ACS Appl Mater Interfaces; 2014 Aug; 6(15):11882-90. PubMed ID: 25000539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.
    Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J
    Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363
    [No Abstract]   [Full Text] [Related]  

  • 12. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery.
    Liu Y; Sun J; Cao W; Yang J; Lian H; Li X; Sun Y; Wang Y; Wang S; He Z
    Int J Pharm; 2011 Dec; 421(1):160-9. PubMed ID: 21945183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
    Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
    Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
    Zhang L; Yao J; Zhou J; Wang T; Zhang Q
    Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers.
    He M; Zhao Z; Yin L; Tang C; Yin C
    Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting.
    Tang B; Zaro JL; Shen Y; Chen Q; Yu Y; Sun P; Wang Y; Shen WC; Tu J; Sun C
    J Control Release; 2018 Jun; 279():147-156. PubMed ID: 29653223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 Receptor Targeting and Endosomal pH-Sensitive Dual Functional Hyaluronic Acid Micelles for Intracellular Paclitaxel Delivery.
    Liu Y; Zhou C; Wang W; Yang J; Wang H; Hong W; Huang Y
    Mol Pharm; 2016 Dec; 13(12):4209-4221. PubMed ID: 27796093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
    Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
    Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
    Obata Y; Tajima S; Takeoka S
    J Control Release; 2010 Mar; 142(2):267-76. PubMed ID: 19861141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.